Literature DB >> 15677555

GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

Xiaofa Qin1, Hui Shen, Min Liu, Qing Yang, Shuqin Zheng, Mary Sabo, David A D'Alessio, Patrick Tso.   

Abstract

Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone secreted in response to meal ingestion by enteroendocrine L cells located predominantly in the lower small intestine and large intestine. GLP-1 inhibits the secretion and motility of the upper gut and has been suggested to play a role in the "ileal brake." In this study, we investigated the effect of recombinant GLP-1-(7-36) amide (rGLP-1) on lipid absorption in the small intestine in intestinal lymph duct-cannulated rats. In addition, the effects of rGLP-1 on intestinal production of apolipoprotein (apo) B and apo A-IV, two apolipoproteins closely related to lipid absorption, were evaluated. rGLP-1 was infused through the jugular vein, and lipids were infused simultaneously through a duodenal cannula. Our results showed that infusion of rGLP-1 at 20 pmol.kg(-1).min(-1) caused a dramatic and prompt decrease in lymph flow from 2.22 +/- 0.15 (SE) ml/h at baseline (n = 6) to 1.24 +/- 0.06 ml/h at 2 h (P < 0.001). In contrast, a significant increase in lymph flow was observed in the saline (control) group: 2.19 +/- 0.20 and 3.48 +/- 0.09 ml/h at baseline and at 6 h of lipid infusion, respectively (P < 0.001). rGLP-1 also inhibited intestinal triolein absorption (P < 0.05) and lymphatic apo B and apo A-IV output (P < 0.05) but did not affect cholesterol absorption. In conclusion, rGLP-1 dramatically decreases intestinal lymph flow and reduces triglyceride absorption and apo B and apo A-IV production. These findings suggest a novel role for GLP-1 in lipid absorption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677555     DOI: 10.1152/ajpgi.00303.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  53 in total

Review 1.  New insights into the molecular mechanism of intestinal fatty acid absorption.

Authors:  Tony Y Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-09-18       Impact factor: 4.686

2.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

3.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

4.  Control of lipid metabolism by tachykinin in Drosophila.

Authors:  Wei Song; Jan A Veenstra; Norbert Perrimon
Journal:  Cell Rep       Date:  2014-09-25       Impact factor: 9.423

Review 5.  Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Authors:  D C Chan; J Pang; G Romic; G F Watts
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

6.  Gut triglyceride production.

Authors:  Xiaoyue Pan; M Mahmood Hussain
Journal:  Biochim Biophys Acta       Date:  2011-10-02

7.  The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Masahiro Kakuda; Junichi Yamakawa; Noboru Takekoshi
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.

Authors:  J Hsieh; C Longuet; C L Baker; B Qin; L M Federico; D J Drucker; K Adeli
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

Review 10.  Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.

Authors:  Teresa Vanessa Fiorentino; Giorgio Sesti
Journal:  Endocrine       Date:  2015-11-26       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.